Go online to PeerView.com/BEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The benefits of prophylaxis with emerging nonfactor therapies in hemophilia have been well-documented, yet despite this clear evidence, many barriers have slowed the integration of effective preventative states in hemophilia A and B. This activity will provide learners with expert insight on new developments with nonfactor prophylaxis in patients with hemophilia A and B, including data from the most recent American Society of Hematology Annual Meeting. Watch an expert-led examination of the evidence supporting novel and emerging nonfactor therapeutics, and hear guidance on implications for real-world practice. Upon completion of this activity, participants should be better able to: Identify barriers and challenges to optimal hemophilia care, including those associated with the use of conventional care options; Evaluate the latest safety/efficacy data supporting the use of novel, emerging nonfactor therapeutics to help guide treatment decisions; Integrate personalized regimens with novel, emerging antibody and siRNA platforms to optimize prophylactic management of hemophilia; and Develop strategies to address practical aspects of hemophilia care associated with the use of novel, emerging nonfactor therapies, including appropriate laboratory monitoring, patient education, adherence counseling, and safety considerations